Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 03/06/2025
• Auteurs : Jean-Baptiste CampsFlorian CafieroPhilippe Chaumet-RiffaudDamien ConceicaoUlysse GodreauÉmilie GuidiAlexandre Lionnet-RollinThéo MoinsPierre-Alexandre NistorBenedetta Salvati
• Organismes : Centre Jean Mabillon École nationale des chartes médialab (Sciences Po) Institut Hospitalo-Universitaire FOReSIGHT École nationale des chartes École nationale des chartes Université Paris Sciences et Lettres Centre Jean Mabillon Centre Jean Mabillon École nationale des chartes École nationale des chartes Centre Jean Mabillon

---

Résumé : Authorship attribution for medieval texts such as those of Chrétien de Troyes poses unique challenges due to textual transmission, language variation, and limited reference corpora. In this context, it might be useful to draw as much stylistic information as possible from the texts, beyond most common features such as function words. This paper presents an ongoing project to include metrical annotation (with a focus on prosody) in the stylometric analysis of Medieval French, to enhance support vector machine (SVM)-based authorship attribution. The case at hand focuses on the attribution of the works of Chrétien de Troyes and his contemporaries.

---

Fichiers liés : abstract_Chrestien_Camps_20250605.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/06/2025
• Auteurs : Xiaojun LiPhilippe CiaisRasmus FensholtJérôme ChaveStephen SitchJ. CanadellMartin BrandtSassan S SaatchiXiangming XiaoShengli TaoHuan WangClément AlbergelHui YangFrédéric FrappartMengjia WangAna BastosPhilippe MaisongrandeYuanwei QinZanpin XingTianxiang CuiLing YuLei HeYi ZhengXiangzhuo LiuYuqing LiuAurelien de TruchisWigneron J.-P.
• Organismes : Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] IT University of Copenhagen Centre de Recherche sur la Biodiversité et l'Environnement University of Exeter CSIRO Environment Business Unit University of Copenhagen = Københavns Universitet Southwest University [Chongqing] University of Oklahoma Peking University [Beijing] Peking University [Beijing] European Centre for Space Applications and Telecommunications Peking University [Beijing] Interactions Sol Plante Atmosphère Zhengzhou University Leipzig University / Universität Leipzig Centre National d'Études Spatiales [Toulouse] Hohai University Interactions Sol Plante Atmosphère Nanjing Forestry University Southwest University [Chongqing] Chinese Academy of Agricultural Sciences National Sun Yat-sen University Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Kayrros SAS Paris France Interactions Sol Plante Atmosphère
• Publié dans Nature Communications le 23/10/2020

---

Résumé :

---

Fichiers liés : s41467-025-59999-2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2025
• Auteurs : Sylvain RheimsFatima ChorfaVéronique MichelEdouard HirschLouis MaillardLuc ValtonFabrice BartolomeiPhilippe DerambureVincent NavarroJulien BiberonArielle CrespelAnca NicaMartine Lemesle MartinLaure MazzolaJerome PetitVincent RosseroSébastien BoulogneMathilde LeclercqLaurent BezinCatherine MercierPascal RoyPhilippe Ryvlin
• Organismes : Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL] Service de Biostatistiques [Lyon] CHU de Bordeaux Pellegrin [Bordeaux] Centre de référence des épilepsies rares [CHRU Strasbourg] Service de neurologie [CHRU Nancy] Ingénierie Moléculaire, Cellulaire et Physiopathologie Centre de recherche cerveau et cognition Centre Hospitalier Universitaire de Toulouse Institut de Neurosciences des Systèmes Service d'Epileptologie et de Rythmologie Cérébrale [Hôpital de la Timone, AP-HM] Service de neurophysiologie clinique Pharmacologie de la mort neuronale et de la plasticité cérébrale CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Centre Hospitalier Régional Universitaire de Tours Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Institut National de la Santé et de la Recherche Médicale Centre Hospitalier Universitaire [Rennes] Laboratoire Traitement du Signal et de l'Image Service de Neurophysiologie Clinique (CHU Dijon) Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Médical de la Teppe Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL] Translational and Integrative Group in Epilepsy Research Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Institut des Epilepsies de l'Enfant et de l'Adolescent Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
• Publié dans Epilepsia Open le 09/01/2019

---

Résumé : Abstract Objective Evaluating the efficacy of an opioid antagonist, naloxone (NLX), to reduce the severity of post‐ictal hypoxemia and immobility after focal to bilateral tonic–clonic seizures (FBTCS). Methods ENALEPSY is a double‐blind placebo (PCB)‐controlled trial conducted in patients with focal epilepsy undergoing long‐term video‐EEG monitoring (LTM). Patients with a FBTCS during LTM were randomized 1:1 to receive intravenous NLX or PCB within the 2 min following the end of FBTCS. After database lock, a discrepancy between the allocated arm and the received treatment was detected, resulting in a 4:1 NLX:PCB ratio. To further explore the efficacy of NLX, we used historical control (HC) data collected in patients included in the REPO 2 MSE study whose characteristics matched those of patients randomized in ENALEPSY. The efficacy of NLX was then assessed versus PCB and versus HC. The primary endpoint was the delay between the end of the seizure and recovery of SpO 2 ≥ 90%. Secondary efficacy outcomes included desaturation nadir and duration of the post‐ictal immobility. Results 33 patients contributed to the NLX group, 7 to the PCB group, and 43 to the HC group. The proportion of FBTCS type 1 or 3 was 84% in NLX, 100% in PCB, and 84% in HC. NLX did not improve the delay of recovery of SpO 2 ≥ 90% or the desaturation nadir. By contrast, the duration of the post‐ictal immobility differed across groups. The time to mobility recovery within the first 5 min post‐ictal was very similar in the PCB (200.3 ± 215.8 s) and HC (194.4 ± 192.0 s) groups, and significantly shorter in the NLX group (128.9 ± 151.1 s) when compared to HC (Hazard Ratio, 1.84; 95% CI, 1.11–3.05; p = 0.021). Significance NLX did not prevent post‐ictal respiratory dysfunction but might reduce the duration of post‐ictal immobility. Confirmation of this effect and its impact on SUDEP risk will require additional studies. Plain Language Summary Release of endogenous opioids might participate in the severity of post‐ictal hypoxemia and immobility after focal to bilateral tonic–clonic seizures (FBTCS). We conducted a multicenter double‐blind randomized placebo‐controlled trial evaluating the efficacy of an opioid antagonist, naloxone (NLX), administered within 2 min following the end of FBTCS. The efficacy of NLX was further explored with a comparison with historical control. NLX did not improve the delay of recovery or the severity of post‐ictal hypoxemia. Post‐ictal immobility was significantly shorter in the NLX group when compared to historical control. The impact of these results on SUDEP prevention will require additional studies.

---

Fichiers liés : Epilepsia Open - 2025 - Rheims - Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2025
• Auteurs : Sylvain DiamantisThibault FraisseEric BonnetVirginie PrendkiClaire AndréjakMarianne AuquierCarla Garcia CarmonaEric FarfourPierre FillatreSébastien GallienGaëtan GavazziAnne-Laure HouistJulie LourtetMathilde PerrinEmilie PietStanislas RebaudetYves RollandJ.P. LanoixAlain Putot
• Organismes : Centre Hospitalier de Melun Service de maladies infectieuses [CH Melun] Centre Hospitalier Alès-Cévennes Université Paris 8 Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] CHU Amiens-Picardie Pneumologie [CHU Amiens] CHU Amiens-Picardie Centre Médical de Forcilles [Lesigny, France] Hôpital Foch [Suresnes] Centre hospitalier Saint-Brieuc Paimpol Tréguier Dynamic Microbiology - EA 7380 Centre Hospitalier Universitaire [CHU Grenoble] CHU Henri Mondor [Créteil] Groupe Hospitalier Paris Saint-Joseph Centre Hospitalier Sud Francilien Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Institut Hospitalier Universitaire HealthAge Centre d'Epidémiologie et de Recherche en santé des POPulations Maladies infectieuses et tropicales [CHU Amiens] Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
• Publié dans Médecine et Maladies Infectieuses Formation le 24/01/2023

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2025
• Auteurs : Aurélien DinhFrançois BarbierJean-Pierre BedosMathieu BlotVincent CattoirYann-Eric ClaessensXavier DuvalPierre FillâtreMaxime GautierYann GueganJarraud SAlban Le MonnierDavid LebeauxPaul LoubetConstance de MargeriePhilippe SerayetYacine Tandjaoui-LambotteEmmanuelle VaronYves WelkerDamien Basille
• Organismes : Hôpital Raymond Poincaré (Garches) [GHU AP-HP Université Paris-Saclay] Hôpital Ambroise Paré [AP-HP] Centre Hospitalier Regional d'Orléans Service de réanimation [CH Versailles] CHU Dijon Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] ARN régulateurs bactériens et médecine Hôpital Princesse Grace [Monaco] Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique Centre hospitalier Saint-Brieuc Paimpol Tréguier Hôpital Simone Veil [Eaubonne] Pathogenèse des légionelles- Legionella pathogenesis [CIRI] Centre National de Référence des Légionelles Hospices Civils de Lyon Groupe Hospitalier Paris Saint-Joseph Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Nîmes Hopital Saint-Louis [AP-HP] Chercheur indépendant Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier Intercommunal de Créteil Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Pneumologie [CHU Amiens]
• Publié dans Médecine et Maladies Infectieuses Formation le 24/01/2023

---

Résumé : La Pneumonie Aiguë Communautaire (PAC) présumée d'origine bactérienne est une pathologie fréquente plus ou moins grave qui peut être prise en charge en ambulatoire ou à l'hôpital, voire en soins critiques. Les Sociétés de Pathologies Infectieuses (SPILF) et de Pneumologie de Langue Française (SPLF) ont coordonné, en partenariat avec les sociétés française de microbiologie (SFM), de médecine d'urgence (SFMU), de radiologie (SFR), de réanimation de langue française (SRLF), et des représentants de la médecine générale, une mise à jour de la prise en charge des recommandations précédentes qui dataient de 2010. Sur le plan thérapeutique, elles définissent le choix de l'antibiothérapie probabiliste initiale, les indications de la bithérapie, des bêta-lactamines anti-Pseudomonas, la durée de traitement antibiotique, ainsi que l'indication et les modalités de prescription des corticostéroïdes systémiques. Sur le plan biologique, les indications des biomarqueurs et des examens à visée microbiologique ont été précisées. Sur le plan radiologique, la place des différents examens pour le diagnostic et le suivi des PAC ont été revues : radiographie, échographie pleuropulmonaire et scanner thoracique.

---

Fichiers liés : Dinh - 2025 - Actualisation des recommandations de prise en charge des pneumonies aiguës communautaires chez l'adulte _MMIFMC-D-25-00002.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2025
• Auteurs : Ludovic SamalinOphelia GodinXavier MoissetAmbre ChalayerAgnes PelletierAntoine LefrerePaul RouxMircea PolosanAnamaria BogdanRaymund SchwanCaroline DubertretBruno AouizerateRaoul BelzeauxRomain ReyDominique JanuelMichel WalterAntoine YrondiEmmanuel HaffenPhilippe CourtetFrank BellivierMarion LeboyerBruno EtainEmilie OliéPierre-Michel Llorca
• Organismes : Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Fondation FondaMental [Créteil] Institut Mondor de Recherche Biomédicale Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] CHU Henri Mondor [Créteil] CHU Clermont-Ferrand Neuro-Dol Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Institut Mondor de Recherche Biomédicale CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Assistance Publique - Hôpitaux de Marseille Institut de Neurosciences de la Timone Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre Hospitalier de Versailles André Mignot Centre de recherche en épidémiologie et santé des populations Centre Hospitalier Universitaire [CHU Grenoble] Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences Fondation FondaMental [Créteil] Centre Hospitalier Princesse Grace Fondation FondaMental [Créteil] Centre Psychothérapique de Nancy [Laxou] Université de Lorraine Hôpital Louis Mourier - AP-HP [Colombes] Institut de psychiatrie et neurosciences de Paris Fondation FondaMental [Créteil] Université Sorbonne Paris Cité Fondation FondaMental [Créteil] Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Institut de Génomique Fonctionnelle Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Centre Hospitalier le Vinatier [Bron] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre de Recherche Clinique [Neuilly-sur-Marne] Université Sorbonne Paris Nord Hopital de Bohars - CHRU Brest Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Toulouse NeuroImaging Center Centre Hospitalier Universitaire de Toulouse Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) Centre d'Investigation Clinique de Besançon Centre Hospitalier Régional Universitaire de Besançon Fondation FondaMental [Créteil] Institut de Génomique Fonctionnelle Centre Hospitalier Régional Universitaire [Montpellier] Fondation FondaMental [Créteil] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Hôpital Lariboisière-Fernand-Widal [APHP] Fondation FondaMental [Créteil] Institut Mondor de Recherche Biomédicale Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] CHU Henri Mondor [Créteil] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Hôpital Lariboisière-Fernand-Widal [APHP] Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand
• Publié dans Journal of Affective Disorders le 31/10/2020

---

Résumé : Introduction: Individuals with bipolar disorder (BD) frequently experience comorbid medical conditions, with migraine being among the most common. While research on migraine prevalence in BD is growing, the associated clinical features, comorbidities, and treatments remain underexplored and sometimes inconsistent. This study aimed to investigate the clinical features and comorbidities associated with migraine in a large cohort of adults with BD. Methods: We assessed 4348 outpatients with BD attending FondaMental Advanced Centers of Expertise. Sociodemographic and clinical data were collected using a standardized procedure. Lifetime diagnoses for medical disorders, including migraine, were based on self-reports, clinician assessments, and medical history reviews. Multivariable logistic regression was used to assess associations between migraine and sociodemographic factors, clinical characteristics, comorbidities, and medications. Results: The prevalence of comorbid migraine in BD was 20 %, with 29.1 % in BD type II and 19.9 % in BD type I. Multivariable analysis found that migraine was associated with younger age (OR = 0.98, CI 95 % 0.97-0.99), females (OR = 2.15, CI 95 % 1.56-2.95), sleep disturbances (OR = 1.06, CI 95 % 1.02-1.11), childhood trauma (OR = 1.01, CI 95 % 1.00-1.02), hypertension (OR = 1.88, CI 95 % 1.13-3.15), psoriasis (OR = 1.61, CI 95 % 1.01-2.56), asthma (OR = 1.65, CI 95 % 1.02-2.67) and lower use of second-generation antipsychotics (OR = 0.65, CI 95 % 0.48-0.87). Conclusion: Migraine is common in BD, especially in younger individuals, females, and those with sleep disturbances or a history of trauma, who also experience a higher clinical burden. These overlapping factors highlight the need for an integrated treatment approach, addressing mood stabilization, sleep management, and trauma support to reduce migraine burden in BD patients.

---

Fichiers liés : Samalin et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 25/05/2025
• Auteurs : Aymeric LanoreEdouard JanuelNathalie BertilleMargherita FabbriLouise-Laure MarianiGraziella MangoneSara SambinPoornima Jayadev MenonFazia Mélissa TirMatthieu BereauWassilios MeissnerClaire ThiriezAna MarquesPhilippe RemyGwendoline DupontElena MoroLuc DefebvreJean-Luc HouetoStéphane ThoboisJean-Philippe AzulayChristian GenySolène FrismandPhilippe DamierCaroline GiordanaGiovanni CastelnovoSolène AnsquerAnne Doe de MaindrevilleSophie DrapierDavid MaltêteChristine TranchantOlivier RascolFlorence TubachYann De RyckeJean-Christophe Corvol
• Organismes : Institut du Cerveau = Paris Brain Institute Assistance publique - Hôpitaux de Paris (AP-HP) Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut du Cerveau = Paris Brain Institute Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre d'investigation clinique de Toulouse Centre d’Excellence en Maladies Neurodégénératives Institut National de la Santé et de la Recherche Médicale Sorbonne Université Institut du Cerveau = Paris Brain Institute INSERM-TRANSFERT [Paris] Centre National de la Recherche Scientifique INSERM-TRANSFERT [Paris] Centre National de la Recherche Scientifique Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Royal College of Surgeons in Ireland Service de neurologie [Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Plateforme F-CRIN Service de Neurologie [CHRU Besançon] Centre Hospitalier Universitaire de Bordeaux FCRIN/FORCE Network Institut des Maladies Neurodégénératives [Bordeaux] University of Otago [Dunedin, Nouvelle-Zélande] New Zealand Brain Research Institute Université de Franche-Comté - UFR des Sciences de la santé Service Neurologie [CHU Clermont-Ferrand] Institut Pascal Plateforme F-CRIN Institut Mondor de Recherche Biomédicale Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) [GIN] Grenoble Institut des Neurosciences Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Régional Universitaire [CHU Lille] Lille Neurosciences & Cognition - U 1172 Epidémiologie des Maladies Chroniques en zone tropicale Plateforme F-CRIN Hospices Civils de Lyon Pathophysiologie de la maladie de Parkinson et des troubles associés Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 Université de Lyon Hôpital de la Timone [CHU - APHM] Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] NS-Park/FCRIN Network Centre de reference des maladies neuromusculaires Nantes-Angers, CHU d'Angers et Nantes NS-Park/FCRIN Network NS-Park/FCRIN Network CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) NS-Park/FCRIN Network Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] CHU Rouen Institut de Génétique et de Biologie Moléculaire et Cellulaire Centre d'investigation clinique de Toulouse Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] Institut du Cerveau = Paris Brain Institute
• Publié dans CNS Drugs le 30/10/2020

---

Résumé : Background: Levodopa, dopamine agonists (DA) and monoamine oxidase inhibitors (MAOI) are all approved first-line therapies for Parkinson's disease (PD), as monotherapy or in combination. Data on their use in the early management of patients with PD in real-life are lacking. Our objective was to assess the impact of early therapeutic strategies on the development of motor and neuropsychiatric complications using a nationwide PD cohort. Methods: NS-PARK is a cohort of patients with PD recruited between 2011 and 2021 from 26 expert centres for PD in France. We analysed the patients with less than 5-years disease duration and no motor complications at inclusion. We used interval censoring survival models to assess the associations between therapeutic strategies (levodopa monotherapy, levodopa alternative therapies or levodopa combinations) and motor fluctuations, dyskinesia, impulse control and related behaviours (ICRBs), apathy, psychosis/hallucination and daytime sleepiness. Analyses were adjusted for sex, age, disease duration, dopaminergic dose and disease severity. Results: We included 1722 patients (38.4% female, median age 67.7 years). At inclusion, 41% received levodopa monotherapy, 31% received levodopa alternative therapies and 28% received levodopa combinations. Compared with levodopa monotherapy, levodopa alternative therapies were associated with a lower dyskinesia risk (hazard ratio (HR) 0.48, 95% confidence interval (CI)[0.28-0.84]), but there was no significant difference in motor fluctuations. Both levodopa alternative and combinations therapies increased ICRBs risk (HR 4.06, 95% CI [2.48-6.67]; HR 5.16, 95% CI [3.00-8.86]) and decreased apathy risk (HR 0.36, 95% CI [0.26-0.49]; HR 0.52, 95% CI [0.39-0.69]). No association was found with psychosis/hallucination or daytime sleepiness. Conclusions: In this real-life cohort, our data supported an association between levodopa alternative therapies and a lower risk of dyskinesia and apathy, but a higher risk of ICRBs compared with levodopa monotherapy. Gov identifier: NCT04888364. Registered June 2021.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 22/05/2025
• Auteurs : Léa ProchassonMakram Mghezzi-HabellahArmelle RoisinMartine PalmaJean-Philippe RobinStève de BossoreilleDavid CluetMalèke MouelhiDidier DecimoAlexandra DesramesThibault ChazeMariette MatondoHélène DutartreMaria-Isabel ThoulouzeFabrice LejeunePierre JalinotS. RétyVincent Mocquet
• Organismes : Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Centre International de Recherche en Infectiologie Virologie Structurale - Structural Virology Spectrométrie de Masse pour la Biologie – Mass Spectrometry for Biology Spectrométrie de Masse pour la Biologie – Mass Spectrometry for Biology Centre International de Recherche en Infectiologie Virologie Structurale - Structural Virology Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule Laboratoire de biologie et modélisation de la cellule
• Publié dans Nucleic Acids Research le 26/10/2020

---

Résumé : The hijacking of CRM1 export is an important step of the retroviral replication cycle. Here, we investigated the consequences of this hijacking for the host. During HTLV-1 infection, we identified that this hijacking by the viral protein Rex favours the association between CRM1 and the RNA helicase UPF1, leading to a decreased affinity of UPF1 for cellular RNA and its nuclear retention. As a consequence, we found that the nonsense-mediated mRNA decay (NMD), known to have an antiviral function, was inhibited. Corroborating these results, we described a similar process with Rev, the functional homolog of Rex from HIV-1. Unexpectedly, we also found that, for HTLV-1, this process is coupled with the specific loading of UPF1 onto vRNA, independently of NMD. In this latter context, UPF1 positively regulates several steps of the viral replication cycle, from the nuclear export of vRNA to the production of mature viral particles.

---

Fichiers liés : gkaf434.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 22/05/2025
• Auteurs : Sylvain FerezCyriac Bouchet-MayerLise Charissou-PujolPhilippe TerralCamille CouvryDamien IssanchouMarie-Pierre JulienClaire PerrinJean-Michel OppertPatrick RitzEmmanuel Disse
• Organismes : Santé, Education et Situations de Handicap Santé, Education et Situations de Handicap Université de Montpellier Centre de Recherche Sciences Sociales Sport et Corps Centre de Recherche Sciences Sociales Sport et Corps Centre Max Weber Université Jean Monnet - Saint-Étienne Université Claude Bernard Lyon 1 - UFR Sciences et techniques des activités physiques et sportives Laboratoire sur les Vulnérabilités et l'Innovation dans le Sport (EA 7428) Laboratoire de sociologie des Territoires, du travail, des âges et de la santé Laboratoire sur les Vulnérabilités et l'Innovation dans le Sport (EA 7428) Nutritional Epidemiology Research Team | Equipe de Recherche en Epidémiologie Nutritionnelle Département de nutrition Centre Hospitalier Universitaire de Toulouse Equipe AGING (CERPOP) Cardiovasculaire, métabolisme, diabétologie et nutrition The Enteric Nervous System in gut and brain disorders [U1235]
• Publié dans BMJ Open le 26/10/2020

---

Résumé : Introduction The effects of bariatric surgery have largely been studied from a medical viewpoint, seeking to measure changes in anthropometric, physiological or quality-of-life factors after the operation. Few studies, however, have focused on the dynamics of lifestyle changes. Yet we know that changing lifestyle habits—which are often part of the established social configurations at the origin of morbid obesity—is essential for a sustainable recovery from obesity. We also know that the major bodily transformations that occur in the six to twelve months following surgery produce a high degree of biographical uncertainty and affect social interactions. From a sociological perspective, the authors propose to study the processes of disruption and re-establishment of lifestyle habits in the first 24 months following bariatric surgery. Methods and analysis The ChiBarAPS study relies on a mixed-method longitudinal survey, comprising three components: qualitative, quantitative, literature and data review. It aims to document three main dimensions, which must be articulated to understand the dynamics of change: (1) the work undertaken by patients on themselves in order to identify and measure the evolutionary effects of surgery, as well as to adapt to them; (2) the experience of using pre- and post-surgery information and support systems, and evaluating their effects on the agency of the people who have undergone surgery; (3) the evolution of social participation and lifestyle habits. The qualitative component concerns a cohort of 30 patients, interviewed in depth (2 hours) on these three dimensions, 6 months, 12 months and 24 months after the operation. The quantitative part uses questionnaires applied to a second group of 200 patients, following the same timeline. Ethics and dissemination This study complies with reference methodology MR004 of the French National Data Protection Authority and was registered by the Data Protection Officer of the University of Montpellier on the activity registry of the institution (24 April 2024). Ethics approval has been obtained from the University of Montpellier ethics research board (n°UM2024-037). Informed consent will be obtained from all participants before data collection. The project has received funding from the French National Research Agency (n°ANR-23-CE41-0020-01) from February 2024 to the end of January 2028. The first results of the research will be disseminated from 2026 onwards to researchers, health professionals and patient support organisations. The results of the study will then be published in peer-reviewed scientific journals, both national and international.

---

Fichiers liés : Article_BMJopen_Publié.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 21/05/2025
• Auteurs : Naëiri PauillacDorothée FailleMialitiana Solo NomenjanaharyMélanie SouvanheuaneNahida Brikci-NigassaAlain AmeriTristan BenoitFrançois DelvoyeBenjamin MaïerBenoit Ho-Tin-NoéMikaël MazighiJean‐philippe DesillesPierre Seners
• Organismes : Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Optimisation thérapeutique en Neuropsychopharmacologie AP-HP - Hôpital Bichat - Claude Bernard [Paris] Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Grand Hôpital de l'Est Francilien Hôpital Robert Ballanger [Aulnay-sous-Bois] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Centre Hospitalier Universitaire de Liège French-Clinical Research Infrastructure Network - F-CRIN [Lille] Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital French-Clinical Research Infrastructure Network - F-CRIN [Lille] Centre hospitalier Saint-Joseph [Paris] Optimisation thérapeutique en Neuropsychopharmacologie French-Clinical Research Infrastructure Network - F-CRIN [Lille] Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Hôpital Lariboisière-Fernand-Widal [APHP] Institut universitaire de France Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital French-Clinical Research Infrastructure Network - F-CRIN [Lille] FHU NeuroVasc [Site Sainte-Anne, Paris] Institut de psychiatrie et neurosciences de Paris Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital French-Clinical Research Infrastructure Network - F-CRIN [Lille] FHU NeuroVasc [Site Sainte-Anne, Paris]
• Publié dans Stroke le 31/10/2020

---

Résumé : Background: Hemorrhagic transformation (HT) frequently occurs in acute ischemic stroke patients with a large vessel occlusion undergoing endovascular therapy (EVT), significantly impacting functional outcomes. We aimed to determine whether an early fibrinogen depletion coagulopathy (FDC) was associated with HT following bridging therapy (ie, intravenous thrombolysis [IVT] followed by EVT), and to identify its associated factors. Methods: We retrospectively analyzed prospectively collected data from 296 patients with acute ischemic stroke with a large vessel occlusion who underwent EVT alone or bridging therapy, with fibrinogen levels measured both before baseline imaging and at the start of the EVT procedure. FDC was defined as a fibrinogen level <2.0 g/L at the start of the EVT procedure, with an absolute decrease >1.0 g/L from baseline. The primary outcome was the occurrence of any HT at 24 to 36 hours. Secondary outcomes included symptomatic HT, parenchymal hematomas, and 3-month mortality. The relationships between FDC and outcomes were studied using multivariable logistic regression analyses, adjusting for relevant confounders. We also studied baseline characteristics associated with FDC occurrence. Results: Of the 296 patients enrolled, 102 (34.5%) experienced HT, and 54 (18.2%) developed FDC. FDC was strongly associated with IVT use (53/161 [32.9%] versus 1/135 [0.7%] in IVT-treated and non-IVT-treated patients, respectively; P<0.01). In patients receiving bridging therapy, FDC occurrence was independently associated with any HT (adjusted odds ratio, 2.33 [95% CI, 1.11-4.91]), symptomatic HT (adjusted odds ratio, 3.35 [95% CI, 1.20-9.40]), parenchymal hematomas (adjusted odds ratio, 2.87 [95% CI, 1.14-7.24]), and 3-month mortality (adjusted odds ratio, 3.82 [95% CI, 1.47-9.93]). None of the 26 patients who received tenecteplase experienced FDC, compared with 53 of 135 (39.3%) patients treated with alteplase (P<0.01). Conclusions: Following bridging therapy, FDC is a frequent event associated with increased risks of any HT, symptomatic HT, parenchymal hematomas, and 3-month mortality. FDC did not occur following IVT with tenecteplase in our cohort, suggesting that the fibrin specificity of thrombolytic agents may play a pivotal role in its development.

---

Fichiers liés : Pauillac et al_Stroke 2025.pdf

---

Source